{"id":"NCT00454207","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"Open Label Study of Sildenafil in Patients With Pulmonary Arterial Hypertension","officialTitle":"A Phase 3, Multi-Center, Open-Label Study to Assess Safety and Efficacy of Sildenafil Citrate 20 mg TID in Subjects With Pulmonary Arterial Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04","primaryCompletion":"2009-02","completion":"2009-02","firstPosted":"2007-03-30","resultsPosted":"2010-09-09","lastUpdate":"2021-02-21"},"enrollment":44,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Hypertension"],"interventions":[{"type":"DRUG","name":"sildenafil citrate (UK-92,480)","otherNames":[]}],"arms":[{"label":"sildenafil citrate (UK-92,480)","type":"EXPERIMENTAL"}],"summary":"To assess the safety of sildenafil 20 mg TID orally given to Japanese pulmonary arterial hypertension patients (Part 1 and 2) To assess the efficacy after 12 weeks of treatment of sildenafil 20 mg TID orally given to Japanese pulmonary arterial hypertension patients (Part 1)","primaryOutcome":{"measure":"Change in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Entered the Study From Part I","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Sildenafil: Part I","deltaMin":84.2,"sd":74.9}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":8,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1481252&StudyName=Open%20Label%20Study%20of%20Sildenafil%20in%20Patients%20with%20Pulmonary%20Arterial%20Hypertension%20%20"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":44},"commonTop":["Nasopharyngitis","Headache","Flushing","Pyrexia","Diarrhoea"]}}